Lymphoma News and Articles

Return to Library

Recent Lymphoma News and Articles

• Scientists at Thomas E. Starzl Transplantation Institute Publish New Data on Ischemia
• Studies from Kinki University Yield New Information about Proteomics
• Study Results from Mayo Clinic Provide New Insights into Epstein-Barr Virus
• Vista Partners Updates Coverage on OncoSec Medical Inc.; Target Price $2.50
• Data from Post Graduate Institute of Medical Education Provide New Insights into T-Cell Lymphoma
• Data on Mantle Cell Lymphoma Detailed by R. Griffiths and Co-Authors
• Findings from Post Graduate Institute of Medical Education Broaden Understanding of Lymphoma
• Research on Science Published by Scientists at School of Pharmacy
• Scientists at Health Sciences Center Target Melanomas

---

Researchers at Sun Yat-sen University Cancer Center Have Published New Data on T-Cell Lymphoma

2012 FEB 8 -- Researchers detail in "Cyclosporine, prednisone, and high-dose immunoglobulin treatment of angioimmunoblastic T-cell lymphoma refractory to prior CHOP or CHOP-like regimen," new data in T-Cell Lymphoma. "Angioimmunoblastic T-cell lymphoma (AITL) is a rare, distinct subtype of peripheral T-cell lymphoma, possessing an aggressive course and poor prognosis with no standard therapy. Twelve patients who have failed at least two initial CHOP or CHOP-like regimens were enrolled in this study and treated with individualized cyclosporine (CsA), prednisone (PDN), and monthly, high-dose intravenous immunoglobulin (HDIVIG)," scientists in Guangdong, People's Republic of China report.

"The dose of CsA was adjusted individually based on the blood trough concentration of CsA and renal function. All patients were examined for response, toxicity and survival. The most significant toxicities (=grade 2) were infection (16.7%), renal insufficiency (8.3%), hypertension (8.3%), diabetes (8.3%) and insomnia (16.7%). Discontinuation of treatment occurred in one patient (8.3%) due to grade 3 renal toxicity and subsequent grade 4 pulmonary infection. Treatment-related death was not observed. The overall response rate was 75.0% (complete response, 33.3%; partial response, 41.7%). With a median follow-up of 25.5 months, the median duration of response was 20 months (range, 12 to 49 months) and the median progression-free survival (PFS) was 25.5 months (range, 10 to 56 months). The 2-year PFS rate was 81.5%," wrote X.G. Chen and colleagues, Sun Yat-sen University Cancer Center.

The researchers concluded: "Our findings indicate the combination of CsA, PDN and HDIVIG is an effective salvage regimen for refractory or relapsed AITL with predictable and manageable toxicity."

Chen and colleagues published their study in Chinese Journal of Cancer (Cyclosporine, prednisone, and high-dose immunoglobulin treatment of angioimmunoblastic T-cell lymphoma refractory to prior CHOP or CHOP-like regimen. Chinese Journal of Cancer, 2011;30(10):731-8).

For more information, contact X.G. Chen, Dept. of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, People's Taiwan.

Keywords: City:Guangdong, Country:People's Republic of China, Region:Asia, Pharmaceuticals, Drugs, Kidney, Hormones, Hematology, Immunology, Nephrology, Immunoproteins, Glucocorticoids, Serum Globulins, T Cell Lymphoma, Lymphatic Diseases, Adrenal Cortical Steroids, Immunoproliferative Disorders, Lymphoproliferative Disorders.

This article was prepared by Biotech Week editors from staff and other reports. Copyright 2012, Biotech Week via NewsRx.com.